Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELCNASDAQ:CSTLNYSE:HHLANASDAQ:PSNL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$12.11-3.6%$10.68$7.58▼$19.77$458.56M0.37290,176 shs115,413 shsCSTLCastle Biosciences$18.75-0.4%$18.31$15.45▼$35.84$541.35M1.03416,908 shs516,017 shsHHLAHH&L Acquisition$10.75-0.3%$10.76$10.20▼$11.30$156.52M-0.01121,140 shs3,300 shsPSNLPersonalis$6.01+3.4%$4.32$1.14▼$7.20$530.83M1.861.04 million shs1.53 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+0.56%+6.62%+16.08%+25.22%-16.27%CSTLCastle Biosciences+2.06%+10.58%+10.51%-2.44%-19.30%HHLAHH&L Acquisition0.00%0.00%0.00%0.00%0.00%PSNLPersonalis-0.85%+14.82%+13.04%+60.06%+343.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELCCelcuity1.9278 of 5 stars3.60.00.00.03.22.50.0CSTLCastle Biosciences2.281 of 5 stars3.53.00.00.01.62.50.0HHLAHH&L AcquisitionN/AN/AN/AN/AN/AN/AN/AN/APSNLPersonalis3.936 of 5 stars2.53.00.04.23.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 3.17Buy$30.80154.34% UpsideCSTLCastle Biosciences 3.00Buy$37.0097.33% UpsideHHLAHH&L Acquisition 0.00N/AN/AN/APSNLPersonalis 3.00Buy$7.6727.57% UpsideCurrent Analyst Ratings BreakdownLatest HHLA, CSTL, CELC, and PSNL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025CSTLCastle BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.005/19/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/15/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/15/2025PSNLPersonalisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/7/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.004/11/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/10/2025PSNLPersonalisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/1/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/1/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$5.48 per shareN/ACSTLCastle Biosciences$347.08M1.56N/AN/A$14.54 per share1.29HHLAHH&L AcquisitionN/AN/A$1.71 per share6.29($1.19) per shareN/APSNLPersonalis$85.69M6.19N/AN/A$2.64 per share2.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$63.78M-$3.03N/AN/AN/AN/A-62.66%-39.78%8/13/2025 (Estimated)CSTLCastle Biosciences-$57.47M-$0.1993.75N/AN/A1.95%1.47%1.27%8/4/2025 (Estimated)HHLAHH&L Acquisition$17.69M-$0.14N/A∞N/AN/A-57.47%-0.35%N/APSNLPersonalis-$108.30M-$1.29N/AN/AN/A-104.52%-66.07%-41.34%8/6/2025 (Estimated)Latest HHLA, CSTL, CELC, and PSNL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CELCCelcuity-$0.95-$0.86+$0.09-$0.86N/AN/A5/6/2025Q1 2025PSNLPersonalis-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million3/31/2025Q4 2024CELCCelcuity-$0.72-$0.85-$0.13-$0.85N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/ACSTLCastle BiosciencesN/AN/AN/AN/AN/AHHLAHH&L AcquisitionN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity0.6510.3510.36CSTLCastle Biosciences0.027.787.64HHLAHH&L AcquisitionN/A0.030.03PSNLPersonalisN/A4.684.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%CSTLCastle Biosciences92.60%HHLAHH&L Acquisition39.24%PSNLPersonalis61.91%Insider OwnershipCompanyInsider OwnershipCELCCelcuity15.77%CSTLCastle Biosciences6.50%HHLAHH&L Acquisition0.54%PSNLPersonalis3.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4037.87 million31.27 millionOptionableCSTLCastle Biosciences54028.87 million25.99 millionOptionableHHLAHH&L AcquisitionN/A14.56 million14.48 millionNot OptionablePSNLPersonalis40088.33 million67.75 millionOptionableHHLA, CSTL, CELC, and PSNL HeadlinesRecent News About These CompaniesBrokerages Set Personalis, Inc. (NASDAQ:PSNL) Price Target at $7.67June 12 at 1:13 AM | americanbankingnews.comPersonalis (NASDAQ:PSNL) Stock Price Up 7.4% - Time to Buy?June 11 at 2:49 PM | marketbeat.comPersonalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of "Buy" from BrokeragesJune 9, 2025 | marketbeat.comPersonalis: Ultra-Sensitive Tech, Ultra-Sensitive RisksJune 8, 2025 | seekingalpha.comPersonalis, Inc. (NASDAQ:PSNL) Shares Purchased by Two Sigma Investments LPJune 7, 2025 | marketbeat.comPersonalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCOJune 4, 2025 | finance.yahoo.comSquarepoint Ops LLC Has $530,000 Stock Position in Personalis, Inc. (NASDAQ:PSNL)June 4, 2025 | marketbeat.comPersonalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCOJune 3, 2025 | businesswire.comPersonalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-TherapyJune 3, 2025 | insidermonkey.comNew Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for RelapseJune 2, 2025 | finance.yahoo.comNew Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for RelapseJune 2, 2025 | businesswire.comMillennium Management LLC Has $7.61 Million Stock Position in Personalis, Inc. (NASDAQ:PSNL)May 28, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires 71,721 Shares of Personalis, Inc. (NASDAQ:PSNL)May 27, 2025 | marketbeat.comPersonalis, Inc. (NASDAQ:PSNL) Shares Bought by Williams Jones Wealth Management LLC.May 23, 2025 | marketbeat.comPersonalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence DetectionMay 22, 2025 | finance.yahoo.comOMERS ADMINISTRATION Corp Buys Shares of 81,400 Personalis, Inc. (NASDAQ:PSNL)May 21, 2025 | marketbeat.comPersonalis, Inc. (NASDAQ:PSNL) Holdings Cut by Cubist Systematic Strategies LLCMay 21, 2025 | marketbeat.com60,127 Shares in Personalis, Inc. (NASDAQ:PSNL) Acquired by Balyasny Asset Management L.P.May 19, 2025 | marketbeat.comPersonalis, Inc. (NASDAQ:PSNL) Stake Raised by Jane Street Group LLCMay 18, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases 242,141 Shares of Personalis, Inc. (NASDAQ:PSNL)May 17, 2025 | marketbeat.comNasdaq Composite Personalis (NASDAQ:PSNL) Advances Precision Medicine GloballyMay 15, 2025 | kalkinemedia.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHHLA, CSTL, CELC, and PSNL Company DescriptionsCelcuity NASDAQ:CELC$12.11 -0.45 (-3.58%) Closing price 04:00 PM EasternExtended Trading$12.09 -0.02 (-0.17%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Castle Biosciences NASDAQ:CSTL$18.75 -0.07 (-0.37%) Closing price 04:00 PM EasternExtended Trading$18.74 0.00 (-0.03%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.HH&L Acquisition NYSE:HHLAHH&L Acquisition Co. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on healthcare or healthcare-related companies in Asian markets. HH&L Acquisition Co. was incorporated in 2020 and is based in Central, Hong Kong.Personalis NASDAQ:PSNL$6.01 +0.20 (+3.44%) Closing price 04:00 PM EasternExtended Trading$6.20 +0.19 (+3.23%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
